Pharmacological treatment for transforming growth factor beta induced corneal dystrophies: what is the way forward?
- 21 March 2023
- journal article
- editorial
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 16 (4) , 275-278
Abstract
Transforming growth factor-beta induced (TGFBI) corneal dystrophies (CDs) are a group of autosomal dominant-inherited disorders with distinct phenotypes, which are characterized by bilateral, progr...Keywords
Funding Information
- Dean’s Grant, Faculty of Medicine and Surgery, University of Malta
This publication has 14 references indexed in Scilit:
- Pharmaceutical modulation of the proteolytic profile of Transforming Growth Factor Beta induced protein (TGFBIp) offers a new avenue for treatment of TGFBI-corneal dystrophyJournal of Advanced Research, 2020
- The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway ApproachFrontiers in Medicine, 2019
- Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case studyExpert Opinion on Drug Safety, 2019
- Strategies for Improving Ocular Drug Bioavailability and Corneal Wound Healing with Chitosan-Based Delivery SystemsPolymers, 2018
- TGF-β1 Regulation of P-JNK and L-Type Calcium Channel Cav1.2 in Cortical NeuronsJournal of Molecular Neuroscience, 2018
- Proteomic profiling of TGFBI‐null mouse corneas reveals only minor changes in matrix composition supportive of TGFBI knockdown as therapy against TGFBI‐linked corneal dystrophiesThe FEBS Journal, 2017
- Involvement of TGF-β Receptor– and Integrin-Mediated Signaling Pathways in the Pathogenesis of Granular Corneal Dystrophy IIInvestigative Ophthalmology & Visual Science, 2010
- Corneal dystrophiesOrphanet Journal of Rare Diseases, 2009
- A subset of patients with epithelial basement membrane corneal dystrophy have mutations inTGFBI/BIGH3Human Mutation, 2006
- Granular Corneal DystrophyOphthalmology, 1994